MSMasoud Salavati

Masoud Salavati

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masoud Salavati has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tailoring Polyetherimide Ultrafiltration Membranes via Non-Solvent- and Vapor-Induced Phase Separation: Effects of Fabrication Pathway and Membrane Formulation on Morphology and Bovine Serum Albumin Separation Performance

    by Mohammad Hosein Moghadasin, Masoud Salavati, Mohammed Majdoub, Ahmed Al-Ostaz, Alexander M. Lopez, Sasan Nouranian

    Polyetherimide (PEI) ultrafiltration membranes were fabricated for bovine serum albumin (BSA) separation using nonsolvent-induced phase separation (NIPS) and vapor-induced phase separation (VIPS). In the NIPS approach, membranes containing varying amounts of Pluronic P-123, with or without graphene nanoplatelets (GNPs), were prepared. Pluronic P-123 acted as a pore-forming agent, while GNPs enhanced permeability without compromising rejection. The membrane with 1 wt.% Pluronic P-123 achieved a pure water flux (PWF) of 355 LMH and 90% BSA rejection. Incorporating 1 wt.% GNPs further improved performance to 747 LMH and 98% rejection. VIPS membranes were fabricated using the same composition as N10, containing 17 wt.% PEI and 1 wt.% Pluronic P-123 without GNPs, to isolate the effect of the fabrication pathway. Increasing vapor exposure time reduced PWF but generally improved BSA rejection, whereas higher RH increased PWF while decreasing rejection. The composition-matched NIPS membrane, N10, exhibited a PWF of 355 LMH and approximately 91% BSA rejection. In comparison, the highest PWF and BSA rejection among the VIPS membranes were 91 LMH and 76.5%, respectively, and the selected balanced VIPS condition at 30 min and 65% RH yielded approximately 49 LMH and 55% rejection. The higher performance of N11, which achieved 747 LMH and 98% rejection, is attributed to GNP incorporation within the NIPS series and was not used to isolate the fabrication-pathway effect. Overall, the composition-matched comparison demonstrates that NIPS produced a more favorable morphology and BSA separation performance than VIPS under the investigated conditions.


  • Open Access

    Overview of Venous Thromboembolism and Emerging Therapeutic Technologies Based on Nanocarriers-Mediated Drug Delivery Systems

    by Masoud Salavati, Arman Arabshomali, Sasan Nouranian, Zia Shariat-Madar

    Venous thromboembolism (VTE) is a serious health condition and represents an important cause of morbidity and, in some cases, mortality due to the lack of effective treatment options. According to the Centers for Disease Control and Prevention, 3 out of 10 people with VTE will have recurrence of a clotting event within ten years, presenting a significant unmet medical need. For some VTE patients, symptoms can last longer and have a higher than average risk of serious complications; in contrast, others may experience complications arising from insufficient therapies. People with VTE are initially treated with anticoagulants to prevent conditions such as stroke and to reduce the recurrence of VTE. However, thrombolytic therapy is used for people with pulmonary embolism (PE) experiencing low blood pressure or in severe cases of DVT. New drugs are under development, with the aim to ensure they are safe and effective, and may provide an additional option for the treatment of VTE. In this review, we summarize all ongoing trials evaluating anticoagulant interventions in VTE listed in clinicaltrials.gov, clarifying their underlying mechanisms and evaluating whether they prevent the progression of DVT to PE and recurrence of thrombosis. Moreover, this review summarizes the available evidence that supports the use of antiplatelet therapy for VTE. Since thrombolytic agents would cause off-target effects, targeted drug delivery platforms are used to develop various therapeutics for thrombotic diseases. We discuss the recent advances achieved with thrombus-targeting nanocarriers as well as the major challenges associated with the use of nanoparticle-based therapeutics.


  • Open Access

    Medicines in Development for Venous Thromboembolism

    by Masoud Salavati, Arman Arabshomali, Sasan Nouranian, Zia Shariat-Madar

    Venous thromboembolism (VTE) is a serious health condition and represents an important cause of morbidity and, in some cases, mortality. According to the latest estimates from the Centers for Disease Control and Prevention, 3 out of 10 people with VTE will have recurrence of clotting event within 10 years. The American Heart Association reports that VTE is more common in people over 40 years of age, and that risk doubles with each decade. The World Health Organization advises that the world’s population of people aged 60 years is going to be doubled by 2050. Deep vein thrombosis (DVT) and pulmonary embolism (PE) are the two main conditions that make up VTE. People with VTE are initially treated with anticoagulants to prevent conditions such as stroke and to reduce the recurrence of VTE. However, thrombolytic therapy is used for people with PE experiencing with low blood pressure or in severe cases of DVT. Despite the approval of direct anticoagulants in 2010, there is clear evidence that the search for new drugs that are more effective or safer than the current antithrombotic treatments continues. Thrombin plays a crucial role in regulating hemostasis and maintaining blood coagulation, and therefore serves as a major target for the treatment of hemostatic disorders such as thromboembolic syndromes, disseminated intravascular coagulation, thrombocytopenia, and acquired hemostatic disorders such as platelet dysfunction and excessive anticoagulation, among other pathologies. This review focuses on the progress in research on new anticoagulants and novel delivery systems for antithrombotic targeting to vascular embolisms.